{"id":"NCT01980095","sponsor":"RedHill Biopharma Limited","briefTitle":"ERADICATE Hp - Treating Helicobacter Pylori With RHB-105","officialTitle":"A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-06","completion":"2015-08","firstPosted":"2013-11-08","resultsPosted":"2017-01-10","lastUpdate":"2019-09-24"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dyspepsia","Helicobacter Pylori Infection"],"interventions":[{"type":"DRUG","name":"RHB-105","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RHB-105","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The \"test and treat\" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients.","primaryOutcome":{"measure":"The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing","timeFrame":"28-56 days after completion of treatment","effectByArm":[{"arm":"RHB-105","deltaMin":59,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["34862940"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":77},"commonTop":["Diarrhoea","Headache","Chromaturia","Abdominal tenderness","Dizziness"]}}